YOLFTbeta
Oncoinvent ASA

Oncoinvent ASA

ONCIN · OL · Healthcare / Biotechnology

69.00NOK-2.00 (-2.82%)

Price History

Full chart

Market Stats

Previous Close71.00
Open74.00
Day Range67.00 – 74.00
52-Week Range40.10 – 144.00
Volume9.05K
Market Cap507.43M
P/E (TTM)0.00
Forward P/E0.00
EPS-86.19
Dividend Yield0.00%
50-Day Avg94.16
200-Day Avg60.03

About

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Oystein Soug M.Sc
  • Employees42
  • HeadquartersGullhaugveien 7, Oslo, Norway, 0484, Norway
  • Websitehttps://www.oncoinvent.com

Leadership

  • Mr. Oystein Soug M.ScChief Executive Officer · b. 1969
  • Ms. Gro Elisabeth HjellumChief Operating Officer
  • Ms. Kristine LofthusChief Production Officer
  • Dr. Kari Myren M.D.Chief Medical Officer
  • Ms. Anne Cecile AlvikHead of Quality Assurance & Employee Representative Director
  • Dr. Anne-Kirsti Aksnes Ph.D.Chief Clinical Officer
  • Dr. Ramzi Amri M.D., Ph.D.Chief Financial Officer
  • Dr. Sara WestrømChief Scientific Officer
  • Ms. Kaja Tunhovd JohansenHead of Quality Control

Financials

Income Statement

Currency: NOK2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue774.00K389.00K354.00K848.00K28.07M
Growth (%)--49.74%-9.00%+139.55%+3210.02%
Cost of Revenue-5.77M5.13M5.31M-
Gross Profit--5.70M-5.07M-2.59M-
Gross Margin--1466.32%-1432.20%-304.95%-
Operating Expense-299.93M186.75M148.65M-
Operating Income-314.46M-305.63M-191.82M-151.23M-158.33M
Operating Margin-40628.17%-78569.41%-54186.16%-17834.20%-564.07%
EBITDA--300.92M-189.60M-125.57M-143.80M
EBITDA Margin--77356.81%-53559.32%-14807.31%-512.30%
Net Income-309.36M-302.12M-190.40M-139.28M-155.07M
Net Income Margin-39969.51%-77666.32%-53785.59%-16424.76%-552.46%
R&D205.82M202.40M107.79M87.69M62.88M
R&D as % of Total Revenue26591.73%52031.62%30448.02%10340.92%224.01%
Interest Expense53.00K321.00K578.00K80.00K23.00K
Interest Expense % of Total Revenue6.85%82.52%163.28%9.43%0.08%

Balance Sheet

Currency: NOK2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets450.24M166.71M174.34M171.01M204.96M
Total Liabilities65.81M78.21M46.86M62.68M58.63M
Total Equity384.43M88.50M127.48M108.33M146.32M
Cash435.89M150.80M155.97M133.67M177.60M

Cash Flow

Currency: NOK2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-303.34M-288.23M-138.11M-153.24M-131.19M
Investing Cash Flow-3.25M3.06M3.69M4.68M
Financing Cash Flow-2.90M224.88M129.61M119.21M
Capital Expenditure03.98M26.83M1.80M119.00K
Free Cash Flow-303.34M-288.23M-164.94M-153.24M-131.31M
FCF to OCF100.00%100.00%119.42%100.00%100.09%

Earnings

Report DateJun 30, 2017Sep 30, 2017Feb 13, 2018May 15, 2018Aug 21, 2018Nov 13, 2018Feb 12, 2019May 8, 2019Aug 19, 2019Nov 19, 2019Feb 11, 2020May 19, 2020Aug 18, 2020Nov 12, 2020Feb 10, 2021May 19, 2021Aug 17, 2021Nov 16, 2021Feb 16, 2022May 24, 2022Aug 23, 2022Nov 15, 2022Feb 16, 2023Jun 22, 2023Aug 23, 2023Nov 14, 2023Feb 14, 2024May 29, 2024Aug 21, 2024Nov 13, 2024Feb 26, 2025Feb 25, 2027
EPS Estimate--------------------------------
EPS Actual-506.11-514.77-689.85-778.86-665.17-497.62-674.94-585.50-686.86-527.88-681.69-528.84-632.29-567.25-622.39-683.17-742.68-588.18-571.57-672.99-697.16-495.87-640.09-597.05-929.72-68.31-99.24-86.08-88.83-40.68-46.94-
Surprise--------------------------------
Timing-------------------------------Pre-market

Key Statistics & Ratios

Market Cap507.43M
Enterprise Value422.31M
Trailing P/E0.00
Forward P/E0.00
Price / Sales20.87
Price / Book6.54
EPS-86.19
Book Value18.01
Revenue (TTM)24.31M
Gross Profit (TTM)24.31M
EBITDA-167.29M
Profit Margin0.00%
Operating Margin-841.07%
Return on Equity-228.06%
Return on Assets-94.22%
Shares Outstanding6.13M
Shares Float3.05M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 19, 20261:100
  • May 30, 20241:100